ClinicalTrials.gov
public full text
Public Domain
3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of 3-AP and doxorubicin in treating patients with metastatic or refractory solid tumors. Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help doxorubicin kill more cancer cells by making them more sensitive to the drug.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer#829752
- Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma#1165220
- Doxorubicin in Treating Women With Advanced Breast Cancer#812769
- Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma#873637
- Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma#867710
Record · ID 1127347
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive